Our head of SEND Services and Chief Toxicologist at PointCross Life Sciences collaborated on a whitepaper on how to assess your SEND readiness. To access the full document, please click here. We have also summarized the document below. When we check nonclinical studies in SEND format with our SEND-ASSURE service, we find that there are significant inconsistencies...
Benchmark Your SEND Readiness
Standards and Ontology Driven Workflow Automation of Clinical Studies - PointCross Life Sciences
Synthetic Dataset for Public Use (PC201708)
Title: How to Integrate Clinical, Biomarker, and Other Disparate Data Sources May 16, 2017
FOSTER CITY, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) — PointCross Life Sciences came out of stealth mode with its Xbiom™ Insights solution for Clinical Biomarker research. With two clients deployed, PointCross is now acquiring new pharma and biotechnology companies who are pursuing precisely targeted therapies in oncology, central nervous system, and cardiovascular. Having proven...
July 20 2022 - PointCross Life Sciences has released the full complement of its eDataValidator™ (eDV) for validating SDTM, ADaM, SEND and Define.XML data for conformance to prevailing FDA, CDISC, and PMDA rules. In use by 5 of the top 10 large pharma and CROs, eDV has now been released as a standalone tool in response to growing...
Assuring your SEND Datasets are Consistent with your Study Report...
Specify, Validate, Package and Review SEND data for FDA Submissions...
Receive a SEND package guaranteed to load into the FDA's Nonclinical Portal...